AGS Therapeutics Announces the Appointment of Dr. Renee T. Williams as an Independent Board Member
Dr. Renee T. Williams, a seasoned Industry Leader, to Play a Key Role in Enhancing AGS Therapeutics's Strategic Direction and Governance and Internationalising its Board of Directors.
PARIS, FRANCE, July 8, 2024 – AGS Therapeutics, a preclinical-stage biotech company pioneering microalgae extracellular vesicles (MEV) as a new, universal delivery system, announced today the appointment of Dr Renee T. Williams as an Independent Director to its board of directors, bringing the total number of board members to seven.
Dr. Renee T. Williams brings a wealth of experience and a proven track record in strategic development within the pharmaceutical and biotech sectors. With over two decades of experience, including significant roles at Eli Lilly and Janssen, Dr. Williams has demonstrated her ability to drive innovation and strategic partnerships across the industry. She recently founded and is Managing Partner of Williams Biotech Consulting, a boutique firm specialising in business development and strategy with expertise in RNA therapeutics, genetic medicines, and non-viral delivery.
As an Independent Director, Dr. Renee T. Williams will provide valuable perspectives on AGS Therapeutics’s strategic initiatives, leveraging her expertise in RNA therapeutics and genetic medicines. Her previous accomplishments include leading complex deal negotiations and strategic operations that have markedly advanced business development and innovation pathways for her previous companies.
"We are thrilled to welcome Dr. Renee T. Williams to our board," said Manuel Vega, CEO of AGS Therapeutics. "Her extensive experience and innovative approach in the biotech field will be invaluable as we continue to pioneer our unique delivery system for new therapeutic modalities and expand our industry reach. Her independent status ensures that she brings a fresh, high-value and unbiased perspective to our board discussions, enhancing our commitment to transparency and good governance."
Dr. Williams expressed her enthusiasm about her new role, stating, "I am both honored and excited to join the board of AGS, and together, look forward to leveraging nature to resolve some of the industry’s most pressing delivery challenges."
Dr. Williams holds a PhD in Chemistry from the University of California, Riverside, and dual MBA degrees from Cornell University and Queen’s University. Her career spans significant scientific and strategic roles, where she has been instrumental in fostering innovation and strategic growth.
About AGS
AGS Therapeutics, based in Paris, France, is a preclinical-stage biotech company pioneering the use of extracellular vesicles from microalgae (MEVs) as a universal delivery system for innovative biologics and gene therapies. AGS has shown MEVs to be a safe, targeted and highly versatile delivery system for mRNA, siRNA, DNA oligos, plasmids, proteins, and peptides relevant to a broad range of human diseases. AGS-M, a company’s CDMO subsidiary, produces the MEVs needed to support R&D and product development from AGS and from companies partnering with AGS. AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae, labelled by the FDA as GRAS for consumption as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with processes that are both eco-friendly and easily scalable. AGS technology platforms (including MEV technology plus payload design and discovery) are a steady source of candidate products. AGS's more advanced products include AGS-1010, a topical product for the treatment of wAMD, and AGS-2010, an oral product for the treatment of an IBD. Through strategic partnerships and a commitment to scientific excellence, the company aims to challenge the delivery landscape and improve the lives of patients across the globe. For more information, visit www.ags-tx.com and www.ags-m.com.
Forward-looking statement
This announcement may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on the future, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this communication.
Contacts
AGS Therapeutics
+33 (0)6 07 16 55 01
Markets @ Listing
+33 (0)6 88 57 05 77
